SEC
SlamSEC
SearchBrowseEarnings

MYRIAD GENETICS INC

Nasdaq:MYGN
In Vitro & In Vivo Diagnostic Substances·SALT LAKE CITY, UT
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States.

CEO
Raha Samraat S.
CFO
Wheeler Benjamin Richard
Revenue
$753.2M
+11.0% YoY
FY 2025
Adj. EBITDA
-$250.2M
-33.2% margin
FY 2025
Net Income
-$263.3M
-35.0% margin
FY 2025
EPS (Diluted)
-$3.18
FY 2025
Stock Price
$5.06
-1.2%
2026-03-11
52W Range
$3.76 – $11.44
P/E Ratio
-1.6x
Market Cap
$473.2M
Cash
$132.1M
FY 2025
Total Debt
$39.6M
FY 2025
Net Cash
$92.5M
FY 2025
Enterprise Value
$380.7M
Debt / EBITDA
0.4x
FY 2025
EV / EBITDA
-1.5x
Employees
—